Status:
WITHDRAWN
Prospective Evaluation of an RDT to Screen for Gambiense HAT and Diagnose P. Falciparum Malaria
Lead Sponsor:
Foundation for Innovative New Diagnostics, Switzerland
Collaborating Sponsors:
Makerere University
Ministry of Public Health, Democratic Republic of the Congo
Conditions:
Human African Trypanosomiasis
Eligibility:
All Genders
6+ years
Brief Summary
A prototype rapid diagnostic test (RDT) to simultaneously screen for gambiense human African trypanosomiasis (HAT) and diagnose P. falciparum malaria (the "HAT/malaria combo") has recently been develo...
Eligibility Criteria
Inclusion
- Age greater than or equal to 6 years
- Provision of signed informed consent. For children (under the age of 18) provision of signed informed consent by a parent or legal guardian and an age appropriate assent.
Exclusion
- Severe anaemia preventing collection of a sample of venous blood
- Severe medical condition preventing informed consent and trial participation (e.g. coma, cognitive impairment, etc.)
- For HAT true negatives only: history of previous HAT infection
Key Trial Info
Start Date :
January 31 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03394976
Start Date
January 31 2022
End Date
December 31 2022
Last Update
January 9 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.